BMS registers Phase 2 depression trial for BMS-986511; adds Alzheimer's PK study for BMS-986446Aug 21Weekly roundup, 6 itemsBristol Myers Squibbentecavir
Prothena reports Q2 2026 results, updates year-end cash guidance to $259 millionAug 6Quarterly updateProthena Corp Public Ltd Co
Sign inSign in